US biotech Arbutus Biopharma (Nasdaq: ABUS) has reacquired the rights to its lead hepatitis B candidate, imdusiran (AB-729), ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for ...

Mabwell’s subsidiary T-mab enters into an agreement with Qilu Pharma for Albipagrastim alfa for injection: Shanghai Monday, June 30, 2025, 15:00 Hrs [IST] Mabwell, an innovative ...

Qilu Pharmaceutical is subsidiary of Qilu Pharmaceutical Group Co., Ltd. About Mabwell. Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the ...

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan ...

SHANGHAI, June 27, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an ...

BEIJING -- The National Natural Science Foundation of China (NSFC) on Monday launched the Private Enterprise Innovation and ...

Arbutus Biopharma had made no secret of its plans to step up its work on imdusiran. | Arbutus had made no secret of its desire to step up its plans for imdusiran. Now, the company has regained the ...

Arbutus reacquires China rights to imdusiran after Qilu ... has regained full global rights to its lead hepatitis B compound imdusiran after mutually agreeing with Qilu Pharmaceutical to end ...